company background image
20D logo

Cidara Therapeutics DB:20D Stock Report

Last Price

€0.62

Market Cap

€59.3m

7D

3.8%

1Y

-63.4%

Updated

20 Mar, 2024

Data

Company Financials +

20D Stock Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.

20D fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Cidara Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cidara Therapeutics
Historical stock prices
Current Share PriceUS$0.62
52 Week HighUS$2.02
52 Week LowUS$0.57
Beta0.94
1 Month Change0%
3 Month Change-3.71%
1 Year Change-63.43%
3 Year Change-67.16%
5 Year Change-72.31%
Change since IPO-95.50%

Recent News & Updates

Recent updates

Shareholder Returns

20DDE BiotechsDE Market
7D3.8%0.06%0.07%
1Y-63.4%28.6%4.9%

Return vs Industry: 20D underperformed the German Biotechs industry which returned 28.1% over the past year.

Return vs Market: 20D underperformed the German Market which returned 5% over the past year.

Price Volatility

Is 20D's price volatile compared to industry and market?
20D volatility
20D Average Weekly Movement9.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 20D has not had significant price volatility in the past 3 months.

Volatility Over Time: 20D's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201273Jeff Steinhttps://www.cidara.com

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company’s lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.

Cidara Therapeutics, Inc. Fundamentals Summary

How do Cidara Therapeutics's earnings and revenue compare to its market cap?
20D fundamental statistics
Market cap€59.26m
Earnings (TTM)-€28.11m
Revenue (TTM)€51.77m

1.2x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
20D income statement (TTM)
RevenueUS$56.54m
Cost of RevenueUS$73.63m
Gross Profit-US$17.08m
Other ExpensesUS$13.61m
Earnings-US$30.70m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin-30.22%
Net Profit Margin-54.29%
Debt/Equity Ratio0%

How did 20D perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.